Scarica l'app Stockscreener
42.19
5.63%
2.25
Dopo l'orario di chiusura:
42.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes (ALKS) finance VP exercises options and sells 16,217 shares - Stock Titan
Alkermes Plc Hits New 52-Week High at $40.78, Up 65% - Markets Mojo
Alkermes showcases data from psychiatry portfolio and sleep research into real world patient experience at spring 2026 scientific conferences - MSN
Alkermes plc stock (IE00B56GVS15): 52-week high after Q1 beat - AD HOC NEWS
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Alkermes stock hits 52-week high at 39.57 USD By Investing.com - Investing.com Nigeria
Alkermes stock hits 52-week high at 39.57 USD - Investing.com
Alkermes to showcase leadership in psychiatry and orexin biology with new data at the American Society of Clinical Psychopharmacology annual meeting - MSN
New orexin data on narcolepsy, schizophrenia at ASCP meeting - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Unlocking Potential With A 23.47% Upside - DirectorsTalk Interviews
Alkermes (ALKS) director logs RSU exercise, tax withholding and new equity grants - Stock Titan
Alkermes (ALKS) director gets new RSUs, options and tax withholding - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
Alkermes (NASDAQ: ALKS) director reports RSU vesting, option grant and tax-share withholding - Stock Titan
[Form 4/A] Alkermes plc. Amended Insider Trading Activity - Stock Titan
Alkermes (ALKS) director receives equity awards and corrects vesting terms - Stock Titan
Alkermes (ALKS) director reports RSU vesting, tax withholding and new stock options - Stock Titan
Alkermes (NASDAQ: ALKS) director logs RSU exercise, new option and RSU grants - Stock Titan
Avoiding Lag: Real-Time Signals in (ALKS) Movement - Stock Traders Daily
Alkermes Shareholders Approve Amended Stock Incentive Plan - The Globe and Mail
LYBALVI data detail real-world relapse and ER visit outcomes - Stock Titan
Alkermes (ALKS) shareholders approve 2018 equity plan, directors and auditor - Stock Titan
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge - TipRanks
Alkermes plc (ALKS) Stock Analysis: Uncovering a 21% Upside Potential in Biopharmaceutical Innovation - DirectorsTalk Interviews
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - MSN
Alkermes plc stock (IE00B56GVS15): M&A deal with Avadel and fresh analyst signals put focus on futur - AD HOC NEWS
Alkermes plc stock (IE00B56GVS15): focus shifts after oncology spin-off and latest quarterly figures - AD HOC NEWS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline - TipRanks
T. Rowe Price (NASDAQ: ALKS) holds 4.66M shares, 2.8% stake - Stock Titan
Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia - Sleep Review
What is HC Wainwright's Estimate for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc $ALKS Shares Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Alkermes stock hits 52-week high at $38.94 By Investing.com - Investing.com South Africa
Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48 - AD HOC NEWS
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alkermes reports encouraging data from Phase III study of Lumryz - Clinical Trials Arena
Alkermes stock hits 52-week high at $38.94 - Investing.com
ALKS Maintained by Baird -- Price Target Raised to $48.00 - GuruFocus
Alkermes (NASDAQ:ALKS) Price Target Raised to $48.00 - MarketBeat
Alkermes Gains Strength On Strong Execution And Strategic Diversification - RTTNews
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH - Citeline News & Insights
Alkermes Earnings Surprise Keeps Nasdaq Composite Watching - Kalkine Media
Alkermes posts late-stage trial win for Lumryz in new sleep disorder - MSN
Alkermes' (NASDAQ:ALKS) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles - Benzinga
Investors Can Find Comfort In Alkermes' (NASDAQ:ALKS) Earnings Quality - 富途牛牛
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 - Quantisnow
Positive Phase 3 Results for Alkermes (ALKS) LUMRYZ in Treating Hypersomnia - GuruFocus
Alkermes (ALKS) Shares Rise on Positive Sleep Disorder Therapy T - GuruFocus
Alkermes stock maintains Buy rating on positive sleep disorder trial By Investing.com - Investing.com South Africa
Alkermes stock maintains Buy rating on positive sleep disorder trial - Investing.com
0.81%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):